ArticleThe Prostate2024

Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis.

LaKendria K Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.